Mihael H. Polymeropoulos

New Capabilities

Leading Vanda through dual drug launches in 2026

Every atypical antipsychotic approved since the early 1990s has worked the same basic way: blocking dopamine receptors in the brain. In the past 17 months, the Food and Drug Administration (FDA) has approved three new psychiatric drugs—including Cobenfy, the first schizophrenia treatment with a genuinely novel mechanism in over 50 years, and now Bysanti, a new chemical entity from Vanda Pharmaceuticals cleared for both bipolar I disorder and schizophrenia. For the roughly 7 million Americans living with these conditions, the options just got meaningfully wider.

Updated Feb 21